WO2010053655A3 - Therapeutic methods with withaferin a and analogs - Google Patents

Therapeutic methods with withaferin a and analogs Download PDF

Info

Publication number
WO2010053655A3
WO2010053655A3 PCT/US2009/060056 US2009060056W WO2010053655A3 WO 2010053655 A3 WO2010053655 A3 WO 2010053655A3 US 2009060056 W US2009060056 W US 2009060056W WO 2010053655 A3 WO2010053655 A3 WO 2010053655A3
Authority
WO
WIPO (PCT)
Prior art keywords
withaferin
analogs
referred
therapeutic methods
hsfl
Prior art date
Application number
PCT/US2009/060056
Other languages
French (fr)
Other versions
WO2010053655A2 (en
Inventor
Mark S. Cohen
Abbas Samadi
Barbara N. Timerman
Original Assignee
University Of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Kansas filed Critical University Of Kansas
Publication of WO2010053655A2 publication Critical patent/WO2010053655A2/en
Publication of WO2010053655A3 publication Critical patent/WO2010053655A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Compounds of Formulas 1 (withaferin A, also referred to as D004), 2 (viscosalactone B, also referred to as E002), and 3 (22R-5β-formyl-6β,27-dihydroxyl-l -oxo-4-norwith-24- enolide, also referred to as O010), as well as salts, prodrugs, analogs, and derivatives thereof are biologically active for modulating Hsp70, Hsp90, and/or HSFl. Also, these compounds can be included in pharmaceutical compositions for administration to a subject for modulating the expression or activity of Hsp70, Hsp90, and/or HSFl in order to produce a therapeutic effect.
PCT/US2009/060056 2008-11-07 2009-10-08 Therapeutic methods with withaferin a and analogs WO2010053655A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11246508P 2008-11-07 2008-11-07
US61/112,465 2008-11-07

Publications (2)

Publication Number Publication Date
WO2010053655A2 WO2010053655A2 (en) 2010-05-14
WO2010053655A3 true WO2010053655A3 (en) 2010-07-15

Family

ID=42153473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/060056 WO2010053655A2 (en) 2008-11-07 2009-10-08 Therapeutic methods with withaferin a and analogs

Country Status (1)

Country Link
WO (1) WO2010053655A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004867C (en) 2008-06-26 2020-09-15 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
US8637494B2 (en) 2010-06-14 2014-01-28 Baylor Research Institute Method of achieving normoglycemia in diabetics by administration of Withaferin A
CA2817773A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
US8598339B2 (en) 2011-02-01 2013-12-03 University Of Kansas Withanolide isolated from Physalis longifolia and analogs and methods of use thereof
WO2012174666A1 (en) 2011-06-22 2012-12-27 UNIVERSITé LAVAL Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
AU2014291615B2 (en) * 2013-07-17 2019-09-26 Council Of Scientific & Industrial Research Pharmaceutical composition for the treatment of diminution of bone tissue
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
US11472832B2 (en) 2013-11-25 2022-10-18 Arna Therapeutics Inc. Withanolides useful for the treatment of neurodegenerative diseases
MX364528B (en) * 2013-11-25 2019-04-30 Imstar Therapeutics Inc Withanolides useful for the treatment of neurodegenerative diseases.
TR201901299T4 (en) * 2013-11-26 2019-02-21 Childrens Medical Ct Corp Compounds for obesity treatment and methods of their use.
WO2016011049A2 (en) 2014-07-14 2016-01-21 Schwendeman Anna Compositions and methods for disease treatment using nanoparticle delivered compounds
KR102638203B1 (en) 2014-09-15 2024-02-19 제브라 덴마크 에이/에스 Arimoclomol formulation
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016160880A1 (en) * 2015-03-31 2016-10-06 Baylor Research Institute Methods and compositions for treating pancreatitis
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
BR112018070653A2 (en) 2016-04-29 2019-02-05 Orphazyme As active pharmaceutical ingredient and composition
KR101802659B1 (en) * 2016-07-04 2017-11-28 경상대학교산학협력단 A composition for preventing or protecting neurodegenerative diseases comprising compound purified from Withania coagulans
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
US20190201327A1 (en) * 2017-09-25 2019-07-04 Ampersand Biopharmaceuticals, Inc. Topical applications of withaferin a
CN111087454B (en) * 2020-02-26 2021-07-27 福建农林大学 Heat shock transcription factor 1 dominant negative effect mutant and application thereof
JP2024500632A (en) 2020-11-19 2024-01-10 ゼブラ デンマーク エー／エス Preparation process of arimoclomol citrate and its intermediates
CN114522173A (en) * 2022-04-08 2022-05-24 中国药科大学 Application of withaferin A in preparation of melanoma treatment drug

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166184A1 (en) * 2002-12-03 2004-08-26 Natreon Inc. Withania somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof
US20040258781A1 (en) * 2002-11-14 2004-12-23 Board Of Trustees Of Michigan State University Cyclooxygenase-2 inhibitory withanolide compositions and method
US20080207574A1 (en) * 2006-03-27 2008-08-28 Royce Mohan Withanolides, probes and binding targets and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040258781A1 (en) * 2002-11-14 2004-12-23 Board Of Trustees Of Michigan State University Cyclooxygenase-2 inhibitory withanolide compositions and method
US20040166184A1 (en) * 2002-12-03 2004-08-26 Natreon Inc. Withania somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof
US20080207574A1 (en) * 2006-03-27 2008-08-28 Royce Mohan Withanolides, probes and binding targets and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D.R. CIOCCA ET AL., CELL STRESS & CHAPERONES, vol. 10, no. 2, 2005, pages 86 - 103 *
H. ICHIKAWA ET AL., MOLECULAR CANCER THERAPY, vol. 5, no. 6, 2006, pages 1434 - 1445 *
W. CHEN ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, no. 25, 20 June 2008 (2008-06-20), pages 17184 - 17193 *
W. LUO ET AL., PNAS, vol. 104, no. 22, 29 May 2007 (2007-05-29), pages 9511 - 9516 *

Also Published As

Publication number Publication date
WO2010053655A2 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
WO2010053655A3 (en) Therapeutic methods with withaferin a and analogs
MX2009011997A (en) Pyrrolopyrimidin-7-one derivatives and their use as pharmaceuticals.
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
TW200738241A (en) Pyridazine derivatives
NO20065904L (en) Therapeutic compounds
NZ627274A (en) Anesthetic compounds and related methods of use
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
TW200608972A (en) Aryl-pyridine derivatives
TW200626558A (en) Indazolone derivatives
MX2009013832A (en) Purine derivatives and their use as modulators of toll-like receptor 7.
MX2014001180A (en) Nuclear transport modulators and uses thereof.
UA106636C2 (en) MORPHOLINOTIAZOLES AS A POSITIVE ALLOSTERIC ALPHA MODULATORS 7
AR047993A1 (en) PHARMACEUTICAL COMPOSITION THAT PIMOBENDAN INCLUDES
MX2010002392A (en) Improved brimonidine compositions for treating erythema.
EA201200618A1 (en) CHROMENON DERIVATIVES WITH ANTI-TUMOR ACTIVITY
MX2010009922A (en) Pyridazinone glucokinase activators.
UA105229C2 (en) Pharmaceutical formulation
CR9703A (en) DERIVATIVES OF PIRAZOLONA
ITBO20110012A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA AND THEIR USE.
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
MX2010001574A (en) Cannabinoid receptor ligands.
MX2012004311A (en) Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes.
MX2010002584A (en) Piperidine derivatives as agonists of muscarinic receptors.
UA113962C2 (en) PHARMACEUTICAL COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE INGREDIENT
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09825177

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09825177

Country of ref document: EP

Kind code of ref document: A2